These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

985 related articles for article (PubMed ID: 30003451)

  • 41. Patient-derived organoids as a platform for modeling a patient's response to chemoradiotherapy in esophageal cancer.
    Karakasheva TA; Gabre JT; Sachdeva UM; Cruz-Acuña R; Lin EW; DeMarshall M; Falk GW; Ginsberg GG; Yang Z; Kim MM; Diffenderfer ES; Pitarresi JR; Li J; Muir AB; Hamilton KE; Nakagawa H; Bass AJ; Rustgi AK
    Sci Rep; 2021 Oct; 11(1):21304. PubMed ID: 34716381
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Appendiceal Cancer Patient-Specific Tumor Organoid Model for Predicting Chemotherapy Efficacy Prior to Initiation of Treatment: A Feasibility Study.
    Votanopoulos KI; Mazzocchi A; Sivakumar H; Forsythe S; Aleman J; Levine EA; Skardal A
    Ann Surg Oncol; 2019 Jan; 26(1):139-147. PubMed ID: 30414038
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hedgehog transcriptional effector GLI mediates mTOR-Induced PD-L1 expression in gastric cancer organoids.
    Koh V; Chakrabarti J; Torvund M; Steele N; Hawkins JA; Ito Y; Wang J; Helmrath MA; Merchant JL; Ahmed SA; Shabbir A; Yan So JB; Yong WP; Zavros Y
    Cancer Lett; 2021 Oct; 518():59-71. PubMed ID: 34126195
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine.
    Praharaj PP; Bhutia SK; Nagrath S; Bitting RL; Deep G
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):117-127. PubMed ID: 29360544
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Human gastric cancer modelling using organoids.
    Seidlitz T; Merker SR; Rothe A; Zakrzewski F; von Neubeck C; Grützmann K; Sommer U; Schweitzer C; Schölch S; Uhlemann H; Gaebler AM; Werner K; Krause M; Baretton GB; Welsch T; Koo BK; Aust DE; Klink B; Weitz J; Stange DE
    Gut; 2019 Feb; 68(2):207-217. PubMed ID: 29703791
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ovarian Cancer Patient-Derived Organoids Used as a Model for Replicating Genetic Characteristics and Testing Drug Responsiveness: A Preliminary Study.
    Chang YH; Wu KC; Wang KH; Ding DC
    Cell Transplant; 2024; 33():9636897241281869. PubMed ID: 39323050
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gastrointestinal Cancer Patient Derived Organoids at the Frontier of Personalized Medicine and Drug Screening.
    Yang Z; Yu J; Wong CC
    Cells; 2024 Aug; 13(16):. PubMed ID: 39195202
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Paired organoids from primary gastric cancer and lymphatic metastasis are useful for personalized medicine.
    Yang R; Qi Y; Kwan W; Du Y; Yan R; Zang L; Yao X; Li C; Zhu Z; Zhang X; Gao H; Cheong IH; Kozlakidis Z; Yu Y
    J Transl Med; 2024 Aug; 22(1):754. PubMed ID: 39135062
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Organoid Culture of Isolated Cells from Patient-derived Tissues with Colorectal Cancer.
    Xie BY; Wu AW
    Chin Med J (Engl); 2016 Oct; 129(20):2469-2475. PubMed ID: 27748340
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative Analysis of Patient-Matched PDOs Revealed a Reduction in OLFM4-Associated Clusters in Metastatic Lesions in Colorectal Cancer.
    Okamoto T; duVerle D; Yaginuma K; Natsume Y; Yamanaka H; Kusama D; Fukuda M; Yamamoto M; Perraudeau F; Srivastava U; Kashima Y; Suzuki A; Kuze Y; Takahashi Y; Ueno M; Sakai Y; Noda T; Tsuda K; Suzuki Y; Nagayama S; Yao R
    Stem Cell Reports; 2021 Apr; 16(4):954-967. PubMed ID: 33711267
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids.
    Gonzalez-Exposito R; Semiannikova M; Griffiths B; Khan K; Barber LJ; Woolston A; Spain G; von Loga K; Challoner B; Patel R; Ranes M; Swain A; Thomas J; Bryant A; Saffery C; Fotiadis N; Guettler S; Mansfield D; Melcher A; Powles T; Rao S; Watkins D; Chau I; Matthews N; Wallberg F; Starling N; Cunningham D; Gerlinger M
    J Immunother Cancer; 2019 Apr; 7(1):101. PubMed ID: 30982469
    [TBL] [Abstract][Full Text] [Related]  

  • 52. "Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction".
    Papaccio F; García-Mico B; Gimeno-Valiente F; Cabeza-Segura M; Gambardella V; Gutiérrez-Bravo MF; Alfaro-Cervelló C; Martinez-Ciarpaglini C; Rentero-Garrido P; Zúñiga-Trejos S; Carbonell-Asins JA; Fleitas T; Roselló S; Huerta M; Sánchez Del Pino MM; Sabater L; Roda D; Tarazona N; Cervantes A; Castillo J
    J Exp Clin Cancer Res; 2023 Jan; 42(1):8. PubMed ID: 36604765
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Patient-Derived Organoids as Therapy Screening Platforms in Cancer Patients.
    Khorsandi D; Yang JW; Foster S; Khosravi S; Hosseinzadeh Kouchehbaghi N; Zarei F; Lee YB; Runa F; Gangrade A; Voskanian L; Adnan D; Zhu Y; Wang Z; Jucaud V; Dokmeci MR; Shen X; Bishehsari F; Kelber JA; Khademhosseini A; de Barros NR
    Adv Healthc Mater; 2024 Aug; 13(21):e2302331. PubMed ID: 38359321
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Patient-derived tumor organoids to model drug response in gastric cancer.
    Vistoso Monreal A; Zhao H; Sedghizadeh PP; Lin DC
    Cell Rep Med; 2024 Jul; 5(7):101650. PubMed ID: 39019014
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity.
    Bruun J; Kryeziu K; Eide PW; Moosavi SH; Eilertsen IA; Langerud J; Røsok B; Totland MZ; Brunsell TH; Pellinen T; Saarela J; Bergsland CH; Palmer HG; Brudvik KW; Guren T; Dienstmann R; Guren MG; Nesbakken A; Bjørnbeth BA; Sveen A; Lothe RA
    Clin Cancer Res; 2020 Aug; 26(15):4107-4119. PubMed ID: 32299813
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids.
    Higa A; Takahashi N; Hiyama G; Tamura H; Hoshi H; Shimomura K; Watanabe S; Takagi M
    J Vis Exp; 2021 Jun; (172):. PubMed ID: 34180908
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Emerging Prospects for the Study of Colorectal Cancer Stem Cells using Patient-derived Organoids.
    Ding L; Yang Y; Lu Q; Cao Z; Weygant N
    Curr Cancer Drug Targets; 2022; 22(3):195-208. PubMed ID: 35078398
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of Trastuzumab Anti-Tumor Efficacy and its Correlation with HER-2 Status in Patient-Derived Gastric Adenocarcinoma Xenograft Models.
    Chen H; Ye Q; Lv J; Ye P; Sun Y; Fan S; Su X; Gavine P; Yin X
    Pathol Oncol Res; 2015 Sep; 21(4):947-55. PubMed ID: 25749810
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Use of Endometrial Cancer Patient-Derived Organoid Culture for Drug Sensitivity Testing Is Feasible.
    Girda E; Huang EC; Leiserowitz GS; Smith LH
    Int J Gynecol Cancer; 2017 Oct; 27(8):1701-1707. PubMed ID: 28683005
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Metabolism of parathyroid organoids.
    Sekhar KR; Codreanu SG; Williams OC; Rathmell JC; Rathmell WK; McLean JA; Sherrod SD; Baregamian N
    Front Endocrinol (Lausanne); 2023; 14():1223312. PubMed ID: 37492197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.